Organ Scoring via SQI Multiplex Diagnostic Panel tests. The Value Opportunity of SQI's assets continues to grow significantly. (In other words, the potential value proposition is increasing) The need for highly quantitative organ scoring diagnostics has never been higher or more relevant to society.
This pandemic will leave the planet with an even greater amount of Lung damage and damage to other organs like Kidney, Liver, Heart etc.
SQI, with the partnership of UHN and the top Lung Transplant Doctor in the World, are leading the way in the field of organ assessment, replacement/transplantation, and rehabilitation.
The ability to confidently triage patients with Covid-19 or other respiratory issues in today's healthcare setting is also of significant and growing value.
As the pandemic shifts phases, Antibody status tests become ever more important. Every individual reacts differently to infection and vaccinations, so determining one's status or level of immunity/protection is important if we are to resume more regular activities. If it is better to be where the puck is going rather than where it is, you will like the fact that SQI is about to be among very few that can provide highly quantitative Antibody data for IgG, IgA, & IgM.
To top all of this off SQI along with McMaster has developed a surface technology with game changing benefits. This technology will not only benefit SQI's stable of tests, but can be licensed out to other major players in the diagnostics field. The Canadian Government has provided SQI & McMaster with grants to further develop this unique surface technology for even greater exploitation.
One FDA submission has already taken place, with two more to follow in the weeks ahead.
The opportunity here is in the Billions and is poised to make a difference to countless lives, yet the story is not shared.